He is the founder and CEO of Evnia Group, a leading biotechnology and regulatory affairs organization headquartered in Denmark.

With a strong academic foundation and extensive experience in Pharma and BioTech, Dr. Vassiliadis has built a career at the intersection of scientific innovation and strategic business execution.

He is recognized for his pioneering work in BioTech innovation, particularly in integrating clinical data generation with regulatory strategy to accelerate market access for medical technologies. Under his leadership, Evnia has supported over 400 manufacturers globally, securing hundreds of CE markings and FDA approvals.

Dr. Vassiliadis is a vocal advocate for embedding Real World Evidence (RWE) into the entire lifecycle of medical devices, and he actively contributes to shaping policy and practice through international forums such as the Riyadh Global Medical Biotechnology Summit. His vision extends beyond compliance, aiming to transform regulatory and clinical affairs into a competitive advantage for BioTech innovators, while fostering cross-border innovation through initiatives like the ARETI Saudi BioTech Deployment Fund and ARETI Europe HealthTech Fund.

A venture capital, venture studio, and venture ecosystems professional with long-term experience across early-stage investing, venture creation, strategic management, institutional frameworks, funding predictability, risk assessment, corporate frameworks, and fund modeling

He currently serves as Fund Manager and spokesperson of the ARETI Europe CVC fund, leading the company’s operational processes, human capital standards, investment intelligence, international relations narrative, and portfolio support.

Giannis and his team support Areti Europe’s thesis formulation, portfolio development, digital storytelling planning, venture screening assessments, systemic and innovation economy diligence, and AIFMD-aligned governance. He has sourced, evaluated, consulted, and advised on over 2,500 startups, spin-offs, corporates, and venture capital, both private equity-backed ventures, primarily at pre-seed, seed, follow-on, and early growth stages.

His track record spans multiple roles within EU-funded programs, Marie Curie initiatives, the Robert Bosch Stiftung Foundation, the EBAN network, the American Farm School, UIC Barcelona, EIT Culture & Creativity, the Creative Valley Innovation Center (Paris), and the Thessaloniki Innovation Zone, among other stakeholders.

He is a multi-time founder himself, a venture studio builder and a venture associate, guiding to M&A exit scenarios. He has collaborated extensively with funds, financial institutions, universities, corporates, and public organizations across Europe, the UK, and the United States, aligning investment strategies with market-driven objectives. Giannis is a practical McKinsey and VC Lab Fellow plus a lifelong learner, focused on deepening his academic insights.

In parallel, he has served as a Lecturer and Visiting Lecturer in business and social sciences at undergraduate and postgraduate levels at European universities and research centers. Giannis is a published author and a researcher in technology entrepreneurship, strategic finance, and venture capital within Managerial Economics at Universitat Internacional de Catalunya/Barcelona. His pan-European research empirically examines venture studios, venture capital firms, business angel networks, bootstrapped strategies, and alternative investment vehicles.

A seasoned BioTech executive and entrepreneur with over three decades of international leadership experience across the pharmaceutical, MedTech, and healthcare IT sectors.

Holding an MBA from the University of Hartford, he has served as CEO of several innovative companies, including Synact Pharma (Nasdaq-listed) and Cercare Medical, and played pivotal roles in strategic exits such as Abbott’s $110 million acquisition of Action Pharma’s lead project.

As founding CEO of Chemometec A/S, he led the company from pre-revenue to public listing and has consistently driven BioTech innovation and market access through executive and board roles in over 30 companies.

His expertise spans financing, commercialization, and M&A, with a track record of successful divestments and IPOs. Mr. Øvlesen continues to shape the BioTech landscape as chairman and board member in ventures like Cereno Scientific, Resother Pharma, and GoPen, leveraging his deep industry insight and entrepreneurial drive.

A distinguished professor, entrepreneur, and innovator in medical imaging, neuroinformatics, and AI-driven healthcare technologies.

He holds a PhD in Medicine from Aarhus University and has held academic and research positions at Harvard Medical School, the Norwegian University of Science and Technology, and Aarhus University, where he currently serves as Professor in Clinical Medicine.

As founder and CEO of Cercare Medical AS, Dr. Mouridsen has led the development of clinical decision support tools for acute stroke care, while also co-founding Mindway AI, a company specializing in responsible gambling technologies with over 12 million active users.

His research has resulted in 88 peer-reviewed publications, including in Nature Medicine, and 7 patent applications, with an h-index of 36 and over 4,500 citations.

Dr. Mouridsen has secured more than 250 million DKK in grants and investments, and received over 20 global innovation awards, including the Philips Global Healthcare Breakthrough and Compliance Innovation of the Year. His leadership spans both academia and industry, with a proven track record in translating research into impactful, scalable solutions.

A distinguished leader in innovation strategy, technology transfer, and economic development, with a career spanning over four decades across academia, government, and industry.

Mr. Crowell showcases a dynamic portfolio of roles including Vice President, Executive Director, and Senior Consultant for institutions such as KAUST, the University of Virginia, The Scripps Research Institute, and the World Bank.

He has been instrumental in launching innovation districts, startup ecosystems, and translational research initiatives in the U.S., Europe, the Middle East, and Asia. He is the recipient of the prestigious Bayh-Dole Award, has testified before Congress on innovation policy, and was invited to the White House for the signing of the America Invents Act.

His current consulting work supports strategic planning and partnership development for organizations like UNC’s Eshelman Innovation, SDBRI, and multiple international clients. His extensive board service and leadership roles further reflect his global influence in shaping innovation ecosystems and advancing public-private collaboration in biopharma and technology.

Dr. Pierrakis focuses on investment strategy, deal evaluation, portfolio development, and ecosystem engagement across the European healthtech sector.

He brings over 20 years of international experience in venture capital, entrepreneurial finance, and innovation across Greece, the United Kingdom, Luxembourg, and Spain.

Before joining Areti Europe, he was Head of Investments Research at Nesta (UK), where he led venture capital market intelligence, sector due diligence, and investment strategy for one of Europe’s leading innovation agencies.

He has advised the European Commission, the European Investment Fund, the World Bank, EBRD, and national governments on venture capital, entrepreneurship, and innovation policy. He is also Associate Professor of Entrepreneurial Finance and Director of the Master’s in Venture Capital & Private Equity at UIC Barcelona.

A deep expert in technology commercialization, innovation strategy, and economic development, with over two decades of experience spanning academia, government, and industry.

Holding a PhD in Chemistry and a BSc in Biomedicinal Chemistry and Neuroscience from Keele University, he has led major initiatives across the UK, the Middle East, and globally.

As Managing Director of Technology Commercialization at Evnia, he designs and implements technology accelerators and strategies in biotechnology. His career includes leadership roles at King Abdullah University of Science and Technology (KAUST), Dhahran Techno Valley Company, and the University of Manchester Intellectual Property Ltd, where he facilitated spin-outs, licensing deals, and multimillion-dollar investment funds. Ian has advised institutions such as the World Bank, PIF (Saudi Arabia), and Qatar University, and has raised several millions in funding for early-stage ventures.

His work has led to the successful, validated scalability of technologies in sectors including energy, semiconductors, medical devices, and advanced materials, with a strong focus on building innovation ecosystems and driving economic impact.

A multidisciplinary healthcare and life sciences professional with a strong academic foundation in Chemical Engineering, Biotechnology, and Digital Health.

Her career bridges scientific research, healthcare innovation, and regulatory strategy, bringing together expertise across the full healthcare innovation lifecycle.

She has extensive research experience in biotechnology, including the development of bio-based technologies, in vitro diagnostic applications, and research initiatives, while actively participating in and coordinating European- and national-funded research programs.

Today, she serves as a Technical Leader for Clinical Documentation and Post-Market Clinical Follow-up (PMCF) activities, supporting medical device manufacturers in generating robust clinical evidence and achieving regulatory compliance.

Through collaborations spanning multiple medical specialties—including orthopedics, cardiology, neurosurgery, oncology, diagnostics, and digital health—she has developed a broad understanding of healthcare needs, innovation challenges, and market access pathways.

A Clinical Study Operations professional with over seven years of experience in clinical research, clinical trial management, and study operations within the medical device and life sciences sectors.

Strong academic background in Cognitive Neuroscience and Clinical Trial Studies, with expertise in research methodology and evidence-based decision-making.

Experienced in managing clinical data, ensuring regulatory compliance, maintaining data integrity, and supporting global clinical studies. Skilled in cross-functional collaboration, project coordination, and optimizing processes to deliver high-quality research outcomes.

Currently pursuing a Master’s in Business Administration to strengthen leadership, strategic thinking, and business management capabilities. Able to bridge scientific expertise with operational excellence to support innovation and organizational success. Recognized for analytical thinking, effective communication, adaptability, and a proactive approach to problem-solving. Passionate about advancing healthcare through high-quality clinical research, continuous improvement, and patient-focused innovation.

A medical doctor and certified corporate mindfulness coach with extensive experience in health, people, and organizational development.

Since 2017, she has worked with leaders, teams, and individuals to strengthen self-leadership, resilience, and well-being, helping them navigate change, complexity, and growth.

By combining medical expertise with coaching, mindfulness, and evidence-based practices, Dr. Maersk delivers practical and sustainable approaches to individual and organizational development. At Areti and Evnia, she supports the implementation of structured HR initiatives that enable high-performing teams and a healthy workplace culture, with a focus on recruitment, onboarding, talent development, and employee support.

Dr. Maersk believes that sustainable business success is built on people having the right mental tools, clear communication, and a culture that promotes both well-being and performance.

An operations and quality management professional specializing in Quality Management Systems (QMS), ISO 9001 compliance, and operational excellence.

He supports the implementation and continuous improvement of audit-ready management systems and organizational governance frameworks across EVNIA Group.

His expertise includes process optimization, quality assurance, HR operations, and business process standardization. Victor also oversees SharePoint governance, digital workplace management, and cross-functional operational initiatives, ensuring regulatory compliance, operational efficiency, and the effective execution of strategic organizational priorities.